Regenerative Medical Technology Group Inc.
Regenerative Medical Technology Group Inc. operates in the regenerative medicine industry in the United States and internationally. It provides products, solutions, equipment, services, and training to doctors and their staff in the application of stem cell therapies. The company is also involved in the treatment of patients; provision of training and seminars; and resale of kits, products, equip… Read more
Regenerative Medical Technology Group Inc. (RMTG) - Total Liabilities
Latest total liabilities as of September 2025: $34.57 Million USD
Based on the latest financial reports, Regenerative Medical Technology Group Inc. (RMTG) has total liabilities worth $34.57 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Regenerative Medical Technology Group Inc. - Total Liabilities Trend (2014–2024)
This chart illustrates how Regenerative Medical Technology Group Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Regenerative Medical Technology Group Inc. Competitors by Total Liabilities
The table below lists competitors of Regenerative Medical Technology Group Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Janus Electric Holdings Ltd
AU:JNS
|
Australia | AU$8.27 Million |
|
Noble Metal Group Incorporated
V:NMG-H
|
Canada | CA$12.14 Million |
|
X Bioscience Public Company Limited
BK:XBIO
|
Thailand | ฿544.00 Million |
|
IMPERIAL TOBACCO
MU:ITB
|
Germany | €23.46 Billion |
|
CRYOLIFE
BE:CYL
|
Germany | €498.40 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Regenerative Medical Technology Group Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 7.65 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Regenerative Medical Technology Group Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Regenerative Medical Technology Group Inc. (2014–2024)
The table below shows the annual total liabilities of Regenerative Medical Technology Group Inc. from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $31.18 Million | +26.36% |
| 2023-12-31 | $24.67 Million | +22.99% |
| 2022-12-31 | $20.06 Million | +24.90% |
| 2021-12-31 | $16.06 Million | +142.30% |
| 2020-12-31 | $6.63 Million | +44.96% |
| 2018-12-31 | $4.57 Million | +77.98% |
| 2017-12-31 | $2.57 Million | -53.48% |
| 2016-12-31 | $5.52 Million | -5.65% |
| 2015-12-31 | $5.85 Million | -51.94% |
| 2014-12-31 | $12.18 Million | -- |